

Eric J Sherman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4770360/publications.pdf>

Version: 2024-02-01

92
papers

5,154
citations

117453

34
h-index

95083

68
g-index

93
all docs

93
docs citations

93
times ranked

6008
citing authors

#	ARTICLE	IF	CITATIONS
1	Primary high-grade non-anaplastic thyroid carcinoma: a retrospective study of 364 cases. <i>Histopathology</i> , 2022, 80, 322-337.	1.6	41
2	Genomic and Transcriptomic Correlates of Thyroid Carcinoma Evolution after BRAF Inhibitor Therapy. <i>Molecular Cancer Research</i> , 2022, 20, 45-55.	1.5	13
3	Targeting the mTOR Pathway in Hurthle Cell Carcinoma Results in Potent Antitumor Activity. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 382-394.	1.9	6
4	Enhancing Radioiodine Incorporation in <i>BRAF</i> -Mutant, Radioiodine-Refractory Thyroid Cancers with Vemurafenib and the Anti-ErbB3 Monoclonal Antibody CDX-3379: Results of a Pilot Clinical Trial. <i>Thyroid</i> , 2022, 32, 273-282.	2.4	30
5	Evaluation of Substantial Reduction in Elective Radiotherapy Dose and Field in Patients With Human Papillomavirus-Associated Oropharyngeal Carcinoma Treated With Definitive Chemoradiotherapy. <i>JAMA Oncology</i> , 2022, 8, 364.	3.4	39
6	American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: Defining advanced thyroid cancer and its targeted treatment. <i>Head and Neck</i> , 2022, 44, 1277-1300.	0.9	41
7	The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers. <i>Nature Communications</i> , 2022, 13, 1450.	5.8	47
8	Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma. <i>European Journal of Endocrinology</i> , 2022, 186, 631-643.	1.9	55
9	A Pilot Study of Durvalumab (MEDI4736) with Tremelimumab in Combination with Image-Guided Stereotactic Body Radiotherapy in the Treatment of Metastatic Anaplastic Thyroid Cancer. <i>Thyroid</i> , 2022, 32, 799-806.	2.4	4
10	Selpercatinib-Induced Hypothyroidism Through Off-Target Inhibition of Type 2 Iodothyronine Deiodinase. <i>JCO Precision Oncology</i> , 2022, , .	1.5	5
11	Outcomes and Toxicities of Nonmedullary Thyroid Tumors Treated with Proton Beam Radiation Therapy. <i>International Journal of Particle Therapy</i> , 2022, 9, 20-30.	0.9	0
12	Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 30-37.	0.8	239
13	Precision Radiotherapy: Reduction in Radiation for Oropharyngeal Cancer in the 30 ROC Trial. <i>Journal of the National Cancer Institute</i> , 2021, 113, 742-751.	3.0	98
14	Outcomes and prognostic factors of major salivary gland tumors treated with proton beam radiation therapy. <i>Head and Neck</i> , 2021, 43, 1056-1062.	0.9	11
15	Any day, split halfway: Flexibility in scheduling high-dose cisplatin—A large retrospective review from a high-volume cancer center. <i>International Journal of Cancer</i> , 2021, 149, 139-148.	2.3	1
16	Co-inhibition of SMAD and MAPK signaling enhances 124I uptake in BRAF-mutant thyroid cancers. <i>Endocrine-Related Cancer</i> , 2021, 28, 391-402.	1.6	10
17	Toxicity Profiles and Survival Outcomes Among Patients With Nonmetastatic Nasopharyngeal Carcinoma Treated With Intensity-Modulated Proton Therapy vs Intensity-Modulated Radiation Therapy. <i>JAMA Network Open</i> , 2021, 4, e2113205.	2.8	34
18	Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 2359-2366.	0.8	64

#	ARTICLE	IF	CITATIONS
19	Abstract CT212: Expanded phase 1/2a study of PLX8394, a novel next generation BRAF inhibitor in patients with advanced, unresectable solid tumors with alterations in BRAF. , 2021, , .		1
20	Intensityâ€modulated radiation therapy and doxorubicin in thyroid cancer: A prospective phase 2 trial. Cancer, 2021, 127, 4161-4170.	2.0	8
21	<i>TERT</i> Promoter Mutations Are Enriched in Oral Cavity Cancers and Associated With Locoregional Recurrence. JCO Precision Oncology, 2021, 5, 1259-1269.	1.5	10
22	The effect of short radiation treatment breaks on chemoâ€radiotherapy for oropharyngeal cancers. Head and Neck, 2021, 43, 3796-3809.	0.9	0
23	Outcomes of multimodal therapy in a large series of patients with anaplastic thyroid cancer. Cancer, 2020, 126, 444-452.	2.0	38
24	Outcomes of surgery and postoperative radiation therapy in managing medullary thyroid carcinoma. Journal of Surgical Oncology, 2020, 121, 234-243.	0.8	4
25	A Phase 1b Study of Cetuximab and BYL719 (Aplisib) Concurrent with Intensity Modulated Radiation Therapy in Stage III-IVB Head and Neck Squamous Cell Carcinoma. International Journal of Radiation Oncology Biology Physics, 2020, 106, 564-570.	0.4	51
26	Platinumâ€based regimens <i>versus</i> cetuximab in definitive chemoradiation for human papillomavirusâ€unrelated head and neck cancer. International Journal of Cancer, 2020, 147, 107-115.	2.3	14
27	Past, present and future of proton therapy for head and neck cancer. Oral Oncology, 2020, 110, 104879.	0.8	22
28	The Importance of Locoregional Therapy in Metastatic Nasopharyngeal Cancer. JAMA Oncology, 2020, 6, 1353.	3.4	4
29	Efficacy of Selpercatinib in <i>RET</i>-Altered Thyroid Cancers. New England Journal of Medicine, 2020, 383, 825-835.	13.9	454
30	Prognostic significance of human papillomavirus and <scp>Epsteinâ€Bar</scp> virus in nasopharyngeal carcinoma. Head and Neck, 2020, 42, 2364-2374.	0.9	12
31	Nasopharynx cancer: Induction or adjuvant? That is the question. Cancer, 2020, 126, 3620-3623.	2.0	1
32	Structural Doubling Time Predicts Overall Survival in Patients with Medullary Thyroid Cancer in Patients with Rapidly Progressive Metastatic Medullary Thyroid Cancer Treated with Molecular Targeted Therapies. Thyroid, 2020, 30, 1112-1119.	2.4	15
33	Last-line local treatment with the Quad Shot regimen for previously irradiated head and neck cancers. Oral Oncology, 2020, 104, 104641.	0.8	16
34	The 3 Bs of cancer care amid the COVIDâ€19 pandemic crisis: â€œBe safe, be smart, be kindâ€”A multidisciplinary approach increasing the use of radiation and embracing telemedicine for head and neck cancer. Cancer, 2020, 126, 4092-4104.	2.0	24
35	Outcomes and toxicities of definitive radiotherapy and reirradiation using 3â€dimensional conformal or intensityâ€modulated (pencil beam) proton therapy for patients with nasal cavity and paranasal sinus malignancies. Cancer, 2020, 126, 1905-1916.	2.0	31
36	Grading of medullary thyroid carcinoma on the basis of tumor necrosis and high mitotic rate is an independent predictor of poor outcome. Modern Pathology, 2020, 33, 1690-1701.	2.9	42

#	ARTICLE	IF	CITATIONS
37	Dissecting Anaplastic Thyroid Carcinoma: A Comprehensive Clinical, Histologic, Immunophenotypic, and Molecular Study of 360 Cases. <i>Thyroid</i> , 2020, 30, 1505-1517.	2.4	143
38	Temporal Lobe Necrosis in Head and Neck Cancer Patients after Proton Therapy to the Skull Base. <i>International Journal of Particle Therapy</i> , 2020, 6, 17-28.	0.9	24
39	Long-term survival in patients with metastatic head and neck squamous cell carcinoma treated with metastasis-directed therapy. <i>British Journal of Cancer</i> , 2019, 121, 897-903.	2.9	32
40	Prolongation of tumour volume doubling time (midDT) is associated with improvement in disease-specific survival in patients with rapidly progressive radioactive iodine refractory differentiated thyroid cancer selected for molecular targeted therapy. <i>Clinical Endocrinology</i> , 2019, 90, 617-622.	1.2	14
41	Phase 2 study of vascular endothelial growth factor trap for the treatment of metastatic thyroid cancer. <i>Cancer</i> , 2019, 125, 2984-2990.	2.0	4
42	Vemurafenib Redifferentiation of <i>BRAF</i> Mutant, RAI-Refractory Thyroid Cancers. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 1417-1428.	1.8	165
43	Treatment modalities and outcomes of Fanconi anemia patients with head and neck squamous cell carcinoma: Series of 9 cases and review of the literature. <i>Head and Neck</i> , 2019, 41, 1418-1426.	0.9	21
44	Trends and Disparities of Proton Therapy Use among Patients with Head and Neck Cancer: Analysis from the National Cancer Database (2005-14). <i>International Journal of Particle Therapy</i> , 2019, 5, 1-10.	0.9	10
45	Long-term outcomes in oral cavity squamous cell carcinoma with adjuvant and salvage radiotherapy after surgery. <i>Laryngoscope</i> , 2018, 128, 2539-2545.	1.1	16
46	Head and neck cancers associated with exposure to the September 11, 2001 World Trade Center terrorist attacks. <i>International Journal of Cancer</i> , 2018, 142, 2485-2490.	2.3	7
47	Phase I study of induction chemotherapy with afatinib, ribavirin, and weekly carboplatin and paclitaxel for stage IVA/IVB human papillomavirus-associated oropharyngeal squamous cell cancer. <i>Head and Neck</i> , 2018, 40, 233-241.	0.9	33
48	Long-term quality of life in older patients with HPV-related oropharyngeal cancer. <i>Head and Neck</i> , 2018, 40, 2321-2328.	0.9	6
49	Targeting VEGF and EGFR: a combination worth re-exploring?. <i>Lancet Oncology</i> , The, 2018, 19, 1007-1009.	5.1	4
50	Integrated Genomic Analysis of H4rthle Cell Cancer Reveals Oncogenic Drivers, Recurrent Mitochondrial Mutations, and Unique Chromosomal Landscapes. <i>Cancer Cell</i> , 2018, 34, 256-270.e5.	7.7	195
51	Intensity-Modulated Radiation Therapy With or Without Concurrent Chemotherapy in Nonanaplastic Thyroid Cancer with Unresectable or Gross Residual Disease. <i>Thyroid</i> , 2018, 28, 1180-1189.	2.4	23
52	Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomes. <i>Endocrine</i> , 2017, 56, 121-128.	1.1	82
53	Proton therapy for head and neck cancer: expanding the therapeutic window. <i>Lancet Oncology</i> , The, 2017, 18, e254-e265.	5.1	106
54	Patterns of Treatment Failure and Postrecurrence Outcomes Among Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma After Chemoradiotherapy Using Modern Radiation Techniques. <i>JAMA Oncology</i> , 2017, 3, 1487.	3.4	146

#	ARTICLE	IF	CITATIONS
55	Tumor volume doubling time of pulmonary metastases predicts overall survival and can guide the initiation of multikinase inhibitor therapy in patients with metastatic, follicular cell-derived thyroid carcinoma. <i>Cancer</i> , 2017, 123, 2955-2964.	2.0	70
56	Impact of concomitant chemoradiation on survival for patients with T1-2N1 head and neck cancer. <i>Cancer</i> , 2017, 123, 1555-1565.	2.0	12
57	The toxicity and efficacy of concomitant chemoradiotherapy in patients aged 70 years and older with oropharyngeal carcinoma in the intensity-modulated radiotherapy era. <i>Cancer</i> , 2017, 123, 1345-1353.	2.0	20
58	Combined high-intensity local treatment and systemic therapy in metastatic head and neck squamous cell carcinoma: An analysis of the National Cancer Data Base. <i>Cancer</i> , 2017, 123, 4583-4593.	2.0	23
59	Phase 2 study evaluating the combination of sorafenib and temsirolimus in the treatment of radioactive iodine-refractory thyroid cancer. <i>Cancer</i> , 2017, 123, 4114-4121.	2.0	59
60	The Molecular Landscape of Recurrent and Metastatic Head and Neck Cancers. <i>JAMA Oncology</i> , 2017, 3, 244.	3.4	191
61	Patterns of nodal failure after intensity modulated radiotherapy for nasopharyngeal carcinoma. <i>Laryngoscope</i> , 2017, 127, 377-382.	1.1	16
62	Genomic analysis of exceptional responders to radiotherapy reveals somatic mutations in <i>ATM</i> . <i>Oncotarget</i> , 2017, 8, 10312-10323.	0.8	31
63	Hypopharyngeal squamous cell carcinoma: Three-dimensional or Intensity-modulated radiotherapy? A single institution's experience. <i>Laryngoscope</i> , 2016, 126, 620-626.	1.1	16
64	Trends in chemoradiation use in elderly patients with head and neck cancer: Changing treatment patterns with cetuximab. <i>Head and Neck</i> , 2016, 38, E165-71.	0.9	26
65	Vemurafenib in patients with BRAFV600E-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial. <i>Lancet Oncology</i> , 2016, 17, 1272-1282.	5.1	290
66	Employment and return to work following chemoradiation in patient with HPV-related oropharyngeal cancer. <i>Cancers of the Head & Neck</i> , 2016, 1, 4.	6.2	19
67	Phase II trial of bevacizumab+cetuximab+cisplatin with concurrent intensity-modulated radiation therapy for patients with stage III/IVB head and neck squamous cell carcinoma. <i>Head and Neck</i> , 2016, 38, E566-70.	0.9	35
68	Strategy of Using Intratreatment Hypoxia Imaging to Selectively and Safely Guide Radiation Dose De-escalation Concurrent With Chemotherapy for Locoregionally Advanced Human Papillomavirus-Related Oropharyngeal Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 9-17.	0.4	121
69	Mammary analog secretory carcinoma of the thyroid gland: A primary thyroid adenocarcinoma harboring ETV6-NTRK3 fusion. <i>Modern Pathology</i> , 2016, 29, 985-995.	2.9	74
70	Proton beam radiation therapy results in significantly reduced toxicity compared with intensity-modulated radiation therapy for head and neck tumors that require ipsilateral radiation. <i>Radiotherapy and Oncology</i> , 2016, 118, 286-292.	0.3	160
71	Irradiation for locoregionally recurrent, never-irradiated oral cavity cancers. <i>Head and Neck</i> , 2015, 37, 1633-1641.	0.9	7
72	Palliative head and neck radiotherapy with the RTOG 8502 regimen for incurable primary or metastatic cancers. <i>Oral Oncology</i> , 2015, 51, 957-962.	0.8	67

#	ARTICLE	IF	CITATIONS
73	Definitive chemoradiation for primary oral cavity carcinoma: A single institution experience. <i>Oral Oncology</i> , 2015, 51, 709-715.	0.8	29
74	Treatment-related toxicities in older adults with head and neck cancer: A population-based analysis. <i>Cancer</i> , 2015, 121, 2083-2089.	2.0	54
75	A nomogram to predict loco-regional control after re-irradiation for head and neck cancer. <i>Radiotherapy and Oncology</i> , 2014, 111, 382-387.	0.3	75
76	The relative prognostic utility of standardized uptake value, gross tumor volume, and metabolic tumor volume in oropharyngeal cancer patients treated with platinum based concurrent chemoradiation with a pre-treatment [18F] fluorodeoxyglucose positron emission tomography scan. <i>Oral Oncology</i> , 2014, 50, 802-808.	0.8	34
77	Patients with low lying lymph nodes are at high risk for distant metastasis in oropharyngeal cancer. <i>Oral Oncology</i> , 2014, 50, 863-868.	0.8	20
78	External beam radiotherapy with or without concurrent chemotherapy in advanced or recurrent non-anaplastic non-medullary thyroid cancer. <i>Journal of Surgical Oncology</i> , 2014, 110, 375-382.	0.8	55
79	Efficacy of concurrent cetuximab vs. 5-fluorouracil/carboplatin or high-dose cisplatin with intensity-modulated radiation therapy (IMRT) for locally-advanced head and neck cancer (LAHNSCC). <i>Oral Oncology</i> , 2014, 50, 947-955.	0.8	51
80	Evaluation of Romidepsin for Clinical Activity and Radioactive Iodine Reuptake in Radioactive Iodine-Refractory Thyroid Carcinoma. <i>Thyroid</i> , 2013, 23, 593-599.	2.4	63
81	Intensity-Modulated Radiotherapy in the Treatment of Oropharyngeal Cancer: An Update of the Memorial Sloan-Kettering Cancer Center Experience. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, 291-298.	0.4	168
82	TALK score: Development and validation of a prognostic model for predicting larynx preservation outcome. <i>Laryngoscope</i> , 2012, 122, 1043-1050.	1.1	25
83	The Role of External Beam Radiation and Targeted Therapy in Thyroid Cancer. <i>Seminars in Radiation Oncology</i> , 2012, 22, 254-262.	1.0	43
84	Concurrent doxorubicin and radiotherapy for anaplastic thyroid cancer: A critical re-evaluation including uniform pathologic review. <i>Radiotherapy and Oncology</i> , 2011, 101, 425-430.	0.3	88
85	Axitinib Is an Active Treatment for All Histologic Subtypes of Advanced Thyroid Cancer: Results From a Phase II Study. <i>Journal of Clinical Oncology</i> , 2008, 26, 4708-4713.	0.8	593
86	Using Patients As Their Own Controls for Cost Evaluation of Phase I Clinical Trials. <i>Journal of Clinical Oncology</i> , 2004, 22, 1308-1314.	0.8	3
87	Alteration of p53 Pathway in Squamous Cell Carcinoma of the Head and Neck: Impact on Treatment Outcome in Patients Treated With Larynx Preservation Intent. <i>Journal of Clinical Oncology</i> , 2002, 20, 2980-2987.	0.8	61
88	Prediction of survival in patients with head and neck cancer using the histoculture drug response assay. , 2002, 24, 437.		3
89	A New Intensified Therapeutic Regimen for Advanced Head and Neck Squamous Cell Carcinomas: Where Does It Fit Among Available Treatment Options?. <i>Cancer Investigation</i> , 2001, 19, 217-218.	0.6	0
90	The collection of indirect and nonmedical direct costs (COIN) form. <i>Cancer</i> , 2001, 91, 841-853.	2.0	31

#	ARTICLE	IF	CITATIONS
91	The collection of indirect and nonmedical direct costs (COIN) form. <i>Cancer</i> , 2001, 91, 841-853.	2.0	1
92	Association of Low and Intermediate Combined Positive Scores With Outcomes of Treatment With Pembrolizumab in Patients With Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma. <i>JAMA Oncology</i> , 0, , .	3.4	4